Pamela Garzone - 09 Jul 2026 Form 4/A - Amendment Insider Report for Cue Biopharma, Inc. (CUE)

Reporting relationship: Director
Issuer ticker: CUE
Reported as of: 09 Jul 2026
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 28 Aug 2026, 17:04:26 UTC
Original report date: 10 Jul 2026
Prior SEC filing: 06 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael Meluzio, Attorney-in-Fact

Key filing fact

Pamela Garzone filed Form 4/A - Amendment for Cue Biopharma, Inc. (CUE) on 28 Aug 2026.

Key facts

This page summarizes Pamela Garzone's Form 4/A - Amendment filing for Cue Biopharma, Inc. (CUE).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 28 Aug 2026, 17:04.

Change

Previous filing in this sequence was filed on 06 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001974756 Primary reporting owner

Garzone Pamela

Relationship: Director
Address: C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON
Signature: /s/ Michael Meluzio, Attorney-in-Fact
Signature date: 28 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CUE transaction

Common Stock

Award

Transaction value
Shares: +18,900
Change %
Price: $0.000000^*
Shares after: 18,900
Date: 09 Jul 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This amendment is being filed solely to correct an administrative calculation error in Column 4 of Table I of the original filing relating to a grant of restricted stock units ("RSUs") to the Reporting Person, which resulted in the number of securities acquired by the Reporting Person being overstated. The original filing incorrectly reported 21,800 shares; the correct amount of shares acquired is 18,900. As a result of this correction, the total amount of securities beneficially owned following the reported transaction in Column 5 has been updated to 18,900. One-third of the shares subject to the RSU vest on each of July 9, 2027, July 9, 2028 and July 9, 2029, subject to the Reporting Person's continued service with the Issuer through each such vest date.